Robert Barrie

3 days ago | pharmaceutical-technology.com | Robert Barrie

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to potential rivals. Over 50 million people in the US live with acne. Maxbelchenko via Shutterstock. Sagimet Bioscience’s denifanstat, a one-daily pill for the treatment of acne, has succeeded in a Phase III trial, with the biotech’s license partner Ascletis Bioscience set to submit the drug for regulatory review in China.

3 days ago | pharmaceutical-technology.com | Robert Barrie

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet. Evrysdi will remain available as a liquid formulation, which originally approved in Europe in 2021. ricochet64 via Shutterstock. Roche has won approval in Europe for a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam), as the drugmaker looks to extend its growing dominance in the neuromuscular disorder market.

4 days ago | pharmaceutical-technology.com | Robert Barrie

AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking. According to a GlobalData report, the global NSCLC market, valued at $30.7bn in 2021, is set to grow to $45.4bn by 2031. Valeriya Zankovych via Shutterstock.

4 days ago | pharmaceutical-technology.com | Robert Barrie

Clinical data for Genmab’s ADC Rina-S is mounting, as the pharma company plans more late-stage trials. Rina-S achieved a 50% confirmed objective response rate (ORR) as a monotherapy. Helena Nechaeva via Shutterstock. Genmab’s antibody drug conjugate (ADC) rinatabart sesutecan (Rina-S) demonstrated positive efficacy in treating patients with endometrial cancer, as investor confidence grows towards the drug’s blockbuster future.

5 days ago | pharmaceutical-technology.com | Robert Barrie

BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A. BMS and BioNTech are now contestants in a fast-moving clinical arena that looks to go beyond traditional single-mechanism checkpoint inhibitors. HJBC via Shutterstock. Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour treatment.